{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007176","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.485240+00:00","generated_at":"2026-06-18T05:27:28.466161+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"dividend","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lipocine Amends Bylaws and Declares Series B Preferred Stock Dividend for Reverse Stock Split Vote","bullets":["Bylaw Amendment adopted March 7, 2023, reducing stockholder quorum from a majority to one-third of outstanding shares.","Board declared dividend of 1/1000th share of Series B Preferred Stock per common share, record date March 24, 2023.","Each Series B Preferred share carries 1,000,000 votes, voting solely on reverse stock split and adjournment proposals.","Series B Preferred is non-transferable except with common stock; shares are subject to automatic redemption before or after the reverse stock split vote.","Press release issued March 10, 2023, announcing the pro rata distribution of Series B Preferred Stock to common stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007176","json":"https://secwatch.observer/filing/0001493152-23-007176.json","markdown":"https://secwatch.observer/filing/0001493152-23-007176.md","text":"https://secwatch.observer/filing/0001493152-23-007176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315223007176/0001493152-23-007176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315223007176/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:27:28.466161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c43e6b0bbf86e8b718af482127e1750b760d274","claim":"Lipocine Inc.: Bylaw amendment to reduce the stockholder quorum requirement from a majority to one-third of outstanding shares entitled to vote (effective 2023-03-07).","evidence_excerpt":"On March 7, 2023, the board of directors the (“ Board ”) of Lipocine Inc. (the “ Company ”), adopted and approved an amendment to the Company’s Amended and Restated Bylaws (the “ Bylaws Amendment ”) in order to change the number of stockholders required to constitute a quorum at a meeting of stockholders, from requiring a majority, to requiring one-third, of the outstanding shares of stock entitled to vote, present in person, by remote communication, or represented by proxy.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315223007176/0001493152-23-007176-index.htm","confidence":0.98,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}